With a PhD in Pharmacology, David possesses 20 years of experience in the oncology field, having worked in several biotechnology and pharmaceutical companies.
Prior to joining NEOMED Institute as Project Director, David held several positions, from research scientist to project director, in small biotechs and large pharmaceutical companies. David has managed several projects from small molecule screening approaches to therapeutic vaccines development. As a Director at GSK Vaccines for over a decade, David worked on novel approaches against cancer in the field of immunotherapy. He has managed several international projects involving multidisciplinary teams from the preclinical to the Phase I/II clinical stages. David has also been a key asset in the evaluation of new opportunities and technologies in the field of cancer immunotherapy.
David brings to NEOMED expertise in the areas of immunotherapy and biologics as well as strong project management. He is also a key resource in evaluating early stage projects that could be selected by NEOMED among available partnering opportunities.
David earned his PhD in 1995 at the Department of Pharmacology from Université de Montréal and a BSc in Biochemistry from Université Laval in Québec City.
Patricia is Director, Scientific Affairs at NEOMED. She is responsible for establishing links with academic institutions in order to identify new innovative projects to help the maturation of active projects and to ensure the visibility of NEOMED with potential partners.
Before joining NEOMED, Patricia worked in the development unit of the Department of Life Sciences of the Atomic Energy Commission in France (Direction des Sciences du Vivant du Commissariat à l’Énergie Atomique), as a technology transfer officer. She then spent four years first as Project Manager and then as Project Director at Univalor, the university technology transfer organization of Université de Montréal and its affiliated health centres. In charge of a portion of the life sciences technologies portfolio, her mission was to assess the technical and commercial potential of inventions to assist in their maturation and transfer to market. As such, Patricia evaluated over 100 projects from academia by ensuring due diligence, protection of intellectual property, analysis of market potential, grant application submission for the maturation of technologies, as well as discussions and negotiations with potential partners that led to research collaborations and licensing agreements, or the creation of spin-offs. Patricia also gained substantial experience in popular science as a scientific mediator in the Palais de la Découverte scientific museum in Paris for several years.
Patricia holds a PhD in Cellular Biology from Université Pierre et Marie Curie in Paris and a Professional Master in Innovation and Commercialization of Research from Université Paris Sud.
Andrew provides expertise in project evaluation and is responsible for the medicinal chemistry components of NEOMED projects. With more than 15 years experience in industry, Andrew held the position of Associate Director at the AstraZeneca Montreal R&D site, managing the computational chemistry group as well as medicinal chemistry. Andrew has successfully worked on multiple projects in lead generation and lead optimization, and managed chemistry teams and partners that have delivered six compounds into clinical trials.
Underlying this achievement is a passion for the integration of computational tools within drug discovery projects and Andrew has been part of various groups within AstraZeneca that have delivered new informatics tools and training. More recently, Andrew led several global projects at AstraZeneca across multiple sites and functions, to deliver new informatics tools to enhance the drug discovery “Design-Make-Test-Analyze” process internally and with external partners.
Andrew received his PhD from the University of Bristol, UK followed by postdoctoral work with professor Stephen Hanessian at Université de Montréal. He has co-authored 16 peer-reviewed scientific publications and is an inventor of 29 patents.
Kemal brings to NEOMED deep expertise in the areas of pharmacology and overall project risk assessment. He is also a key resource in evaluating early stage projects that could be selected by NEOMED among available partnering opportunities.
Before joining NEOMED, Kemal was Director of the Montreal Discovery Portfolio at AstraZeneca since 2007. During that time, he also served on several global teams managing AstraZeneca’s Neuroscience discovery portfolio, such as the CNS/Pain Lead Optimization Projects Network, the Lead Generation Team, and the Portfolio Management Team. He had relocated to Montreal in 1994, to become one of the founding members of the Astra Pain Research Unit, where he established the In Vitro Pharmacology section. In the years following the Astra merger with Zeneca, Kemal became Director of the Molecular Pharmacology Department, and contributed to the delivery of several candidate drugs targeting various GPCRs, ion channels, and enzymes. Kemal also led several target identification and lead generation projects, served on lead optimization project teams, and contributed to the evaluation of various external project opportunities. Kemal began his professional research career in 1988 as a postdoctoral fellow at the National Institute of Health (NICHD in Bethesda, MD), where he was the recipient of an Intramural Research Training Award covering his work on the mechanism and modulation of neuro-secretion. Subsequently, as a Staff Fellow at NIMH (Washington, D.C.), he studied the in vitro pharmacology of Neuropeptide FF receptors.
Kemal earned his PhD in 1987 in Pharmacology and Therapeutics at the University of Florida, an MSc from the Marine Science Institute of Middle East Technical University in Turkey, and a BSc in Biochemistry from the State University of New York at Binghamton. He received both the New York State Regents Scholarship and the S.U.N.Y. Foundation Scholarship. He has 37 publications in peer-reviewed journals, one patent, and published a book chapter on the in vitro pharmacology of cloned human opioid receptors.
Bill serves in the evaluation of chemical assets of early opportunities and is responsible for the medicinal chemistry strategies for NEOMED projects.
Bill was most recently responsible for leading multidisciplinary teams that were responsible for evaluating external opportunities for AstraZeneca, and has also led multidisciplinary project teams that have advanced two compounds into Phase II studies. Following his move to AstraZeneca in 1996, he first led medicinal chemistry projects delivering four clinical candidates. Bill started his drug discovery career in 1990 at BioChem Pharma where he led medicinal chemistry projects in the field of antiviral therapies and received the BioChem Excellence award in both 1993 and 1994.
Bill received his PhD from the University of Ottawa and did postdoctoral research at Stanford and Duke Universities. He has co-authored 35 peer-reviewed scientific publications and is an inventor on 33 patents.
Ahmad brings to NEOMED a wealth of expertise in drug discovery and development from a wide range of therapeutic fields. His drug discovery background includes working at large pharmaceutical companies, startup biotech, and CRO organizations in the US, Canada, and most recently in India. Ahmad plays a key role in the evaluation of projects and partnering opportunities presented to NEOMED.
Before joining NEOMED, Ahmad was Vice President and Head of Discovery Biology at ADVINUS Therapeutics (Pune, India) where he led the biology team for internal drug discovery programs and international collaborations. Ahmad has worked at multiple start up drug discovery organizations including GPCR BioSciences Inc. (Laval, QC), Acucela (Seattle, WA), and Avance Pharma (Laval, QC). He started his drug discovery career at Schering-Plough Research Institute (Kenilworth, NJ) currently part of Merck (NJ, USA). Throughout his career, he initiated and contributed to numerous novel drug discovery programs leading to multiple clinical candidates. His contributions span CV, CNS, GI, obesity, diabetes, ocular, immunology, inflammation, oncology, and antiviral therapeutics. Ahmad is author of over 65 publications in peer-reviewed journals.
Ahmad earned his PhD in Pharmacology and Toxicology from the University of British Columbia Faculty of Pharmaceutical Sciences. Following his PhD, Ahmad performed his postdoctoral research at the University of Calgary Faculty of Medicine and was Associate Research Scientist at Yale University School of Medicine, Department of Pharmacology.
Responsible for the NEOMED Institute is a highly professional, dynamic, and experienced team that provides support to the Institute and resident companies’ activities.
At the NEOMED Institute, Pascal establishes and manages analytical services and instrumentation. Some of the main assays/processes he is responsible for are high-throughput Log D and solubility determinations, and chiral and achiral compound purification by HPLC-MS and SFC-MS. He also offers other types of services such as consulting (purification, instrument, and software training, etc.), and instrument maintenance and troubleshooting. These services are not exclusive to internal resident companies; they are also available to external parties.
Pascal brought to the NEOMED Institute over 10 years of analytical chemistry experience within the pharmaceutical industry. He began his career in 2003 with AstraZeneca as a member of the analytical chemistry group and then moved to Boehringer Ingelheim in 2010, where he was part of the analytical chemistry and purification team. Over the years, he has been involved in the implementation and optimization of many assays and processes such as physical chemistry properties determination, automated compound purification services, (single compound and library), and compound management. One of his major accomplishments was the introduction of the SFC (supercritical fluid chromatography) technology both at AstraZeneca and Boehringer Ingelheim, where he became an SFC specialist responsible for chiral and achiral compound analysis and purification. Pascal received his MSc in Chemistry and Biochemistry from Concordia University in 2002.
As Director of both the Saint-Laurent and Laval sites, Dominic’s mission is to understand and meet the specific needs of the Institute’s clients. With a win-win solution approach, he aims to develop a service optimized for all tenants: Each stakeholder is important. Dominic is responsible for all operations in connection with the NEOMED Institute as well as the support services offered to resident companies, such as security and information technology.
With a Master degree in Cellular Biology from the Université de Sherbrooke (2003), Dominic worked for 12 years in the biopharmaceutical field (ID Biomedical, GSK Vaccines). He gained expertise in the fields of analytical research, quality control, operational excellence, and management. For eight years, Dominic was part of a group dedicated to the physicochemical characterization of candidate vaccines. During this time, he familiarized himself with the instrumentation used in analytical chemistry. He has held the positions of Research Associate, Analytical Tests Supervisor, Laboratory Coordinator, and also served as Interim Manager for the Quality Assurance department.
In 2013, Dominic took over the management of technical services at GSK Vaccines. This department oversaw several service groups, such as building maintenance, logistics, and equipment validation. As a function of his responsibilities, he successfully led the redesign of the Laval site’s office space, in addition to building an open-concept workspace. Dominic was also responsible for the implementation of projects related to the environment / health / safety, to quality assurance, and process optimization (Lean Culture). His leadership and organizational skills were put to use with several mandates outside of the regular scope of his functions.